#	Pagina
attuale pagina	/open-h2020/projects/213047/index.html
-1	/open-h2020/per-topic/deviations/list/index.html

Opendata, web and dolomites

RESTORE SIGNED

NEURONAL SELF-RENEWAL BY ANTIGEN-SPECIFIC TOLERIZATION IN MULTIPLE SCLEROSIS REINSTALLING THE BALANCE BETWEEN INFLAMMATION AND REGENERATION

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

RESTORE project word cloud

Explore the words cloud of the RESTORE project. It provides you a very rough idea of what is the project "RESTORE" about.

context inducing renewal chronic radiological tolerance capacity first breakthrough reactions drive hypothesize cells healthcare nl neurodegenerative team outcome pathogens safeguarding efforts reducing efficacy autoreactive central restore thereby cancer accessibility clinical self restoring bm1305 damaging traumatic innovative patient protective balance trials therapy practicality antigen lives centralized single collaborative coordinated safely action inflammation suffering countries remaining approvals regulatory neuronal patients toldc immune people untreatable therapeutic dendritic data correlates cure 500 joins multiple nervous immunity safety immunomonitoring monitoring additional centers mri clinic place neurodegeneration compare repair consented es proof ms sclerosis biobanking assaults inflammatory multidisciplinary disabling neurological ger center young adults disease network cell

Project "RESTORE" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITEIT ANTWERPEN Organization address address: PRINSSTRAAT 13 city: ANTWERPEN postcode: 2000 website: www.ua.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Belgium [BE]
Project website	https://www.h2020restore.eu/
Total cost	5˙357˙032 €
EC max contribution	5˙357˙032 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2017-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2018
Duration (year-month-day)	from 2018-01-01 to 2022-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITEIT ANTWERPEN UNIVERSITEIT ANTWERPEN Organization address address: PRINSSTRAAT 13 city: ANTWERPEN postcode: 2000 website: www.ua.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (ANTWERPEN)	coordinator	911˙176.00
2	INSTITUT CATALA DE LA SALUT INSTITUT CATALA DE LA SALUT Organization address address: GRAN VIA DE LES CORTS CATALANES 587 city: BARCELONA postcode: 8007 website: http://www.gencat.cat/ics/germanstrias/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	1˙170˙212.00
3	Stichting Sanquin Bloedvoorziening Stichting Sanquin Bloedvoorziening Organization address address: Plesmanlaan 125 city: Amsterdam postcode: 1006 AN website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Amsterdam)	participant	911˙250.00
4	UNIVERSITAIR ZIEKENHUIS ANTWERPEN UNIVERSITAIR ZIEKENHUIS ANTWERPEN Organization address address: WILRIJKSTRAAT 10 city: EDEGEM postcode: 2650 website: www.uza.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (EDEGEM)	participant	660˙056.00
5	UNIVERSIDAD DE NAVARRA UNIVERSIDAD DE NAVARRA Organization address address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL city: PAMPLONA postcode: 31080 website: www.unav.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (PAMPLONA)	participant	625˙000.00
6	ICOMETRIX NV ICOMETRIX NV Organization address address: KOLONEL BEGAULTLAAN 1B city: LEUVEN postcode: 3012 website: http://www.icometrix.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (LEUVEN)	participant	530˙500.00
7	WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER Organization address address: SCHLOSSPLATZ 2 city: MUENSTER postcode: 48149 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENSTER)	participant	363˙837.00
8	STICHTING LYGATURE STICHTING LYGATURE Organization address address: JAARBEURSPLEIN 6 city: UTRECHT postcode: 3521 AL website: http://www.lygature.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	participant	185˙000.00

Map

Project objective

Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system for which no cure is currently available. It is the leading cause of non-traumatic disabling neurological disease in young adults with more than 500,000 people affected in Europe. As chronic inflammatory processes drive the neurodegeneration, we hypothesize that improved clinical outcome can be achieved by restoring the balance between inflammation and the remaining capacity of neuronal self-renewal. In this context, cell therapy that specifically targets the damaging immune reactions that cause MS, thereby reducing the autoreactive, inflammatory assaults in MS without affecting protective immunity against pathogens and cancer, can be a promising approach to allow for more repair. Recently, we set-up a collaborative network of European centers working in cell therapy (COST Action BM1305). From this, a multidisciplinary team from four different EU countries (B, ES, NL and GER) with two additional partners now aims to safely reach the next level of testing and joins efforts to bring antigen-specific cell therapy for MS to the clinic. Our objectives are to evaluate safety, clinical practicality and demonstrate first proof-of-principle of therapeutic efficacy of antigen-specific tolerance-inducing dendritic cells (tolDC) in MS patients in two single-center clinical trials. All regulatory approvals are already in place. Coordinated patient monitoring and centralized MRI monitoring, including radiological correlates of neurodegeneration, and immunomonitoring will enable us to directly compare results between trials and enable consented biobanking, data safeguarding and accessibility to support future efforts in the field of MS therapy. ReSToRe focuses on the advancement of an innovative cell therapy approach with the potential to improve the lives of patients suffering from MS, a currently untreatable disease. This would represent a breakthrough for healthcare in MS.

Deliverables

List of deliverables.
Certificates of clinical training	Documents, reports	2019-08-30 14:59:36

Take a look to the deliverables list in detail: detailed list of RESTORE deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Willekens B, Presas-RodrÃguez, Mansilla M, Derdelinckx J, Lee W-P, Nijs G, De Laere M, Wens I, Cras P, Parizel PM, Van Hecke W, Ribbens A, Billiet T, Adams G, Couttenye M, Navarro-Barriuso J, Teniente-Serra A, Quirant-SÃ¡nchez B, LÃ³pez-DÃaz de Cerio A, InogÃ©s S, PrÃ³sper F, Kip A, Verheij H, Gross CC, Wiendl H, van Ham SM, ten Brinke A, Barriocanal AM, Massuet-VilamajÃ³ A, Hens N, Berneman Z, Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonized study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration published pages: , ISSN: 2044-6055, DOI:	BMJ Open accepted for publication 23/7/2	2019-09-05
2018	Barbara Willekens, Nathalie Cools Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis published pages: 401-410, ISSN: 1172-7047, DOI: 10.1007/s40263-018-0518-4	CNS Drugs 32/5	2019-09-05
2019	Anja ten Brinke, Marc Martinez-Llordella, Nathalie Cools, Catharien M. U. Hilkens, S. Marieke van Ham, Birgit Sawitzki, Edward K. Geissler, Giovanna Lombardi, Piotr Trzonkowski, Eva Martinez-Caceres Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective published pages: , ISSN: 1664-3224, DOI: 10.3389/FIMMU.2019.00181	Frontiers in Immunology 10	2019-09-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESTORE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESTORE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More